ETERN Therapeutics of Shanghai closed a Series B funding to advance its Protein Liquid-Liquid Phase Separation (LLPS) technology. Established in 2018, ETERN, a clinical-stage company, said its LLPS technology focuses on developing molecules for previously undruggable targets. ETERN will use the capital to advance several novel programs through discovery and clinical development. The B round, whose size was not disclosed, was co-led by GL Ventures and AstraZeneca-CICC Healthcare Fund, with participation from new investor Morningside Ventures. More details.... Share this with colleagues: // //